GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

Boston Scientific (NYSE:BSX – Get Free Report) had its price objective hoisted by research analysts at Stifel Nicolaus from ...

Within Neuromodulation, Boston Scientific’s pain business is consistently gaining traction, banking on strength in Spinal cord stimulation (SCS), driven by its innovative Alpha portfolio with ...

A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal ...

Boston Scientific (NYSE:BSX – Get Free Report) had its price objective lifted by equities research analysts at Raymond James ...

Therapeutic breakthroughs in neuromodulation merge wearable technologies, deep brain implants, and tailored stimulations ...

Spinal Cord Stimulators Market. The global spinal cord stimulators market is on an accelerated growth path, projected to ...